NORML Pushes for Voice in DEA Cannabis Rescheduling Hearings
Cannabis advocacy group seeks participation in June 29 DEA hearing on Schedule III reclassification, potentially influencing regulatory outcome.
The National Organization for the Reform of Marijuana Laws has formally requested participation in the Drug Enforcement Administration's June 29 administrative hearing on cannabis rescheduling. The hearing will examine the Department of Health and Human Services' 2023 recommendation to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, marking a critical juncture for federal cannabis policy.
NORML's involvement could amplify advocacy perspectives during the formal review process, potentially strengthening arguments for rescheduling. The organization brings decades of legal expertise and policy advocacy to proceedings that will determine whether cannabis maintains its current classification alongside heroin and LSD, or moves to Schedule III with drugs like ketamine and anabolic steroids.
The rescheduling decision carries substantial financial implications for cannabis operators, particularly multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF). Schedule III classification would eliminate the punitive 280E tax provision that prevents cannabis companies from deducting standard business expenses, potentially improving margins by 15-40% across the sector.
Industry observers view the June hearing as procedural rather than substantive, given the DEA's limited grounds for rejecting HHS medical recommendations under existing law. However, NORML's participation ensures consumer advocacy voices join industry stakeholders in formal proceedings, potentially addressing concerns about corporate capture of the rescheduling process.
The timeline for final rescheduling remains fluid, with implementation potentially extending into 2025 depending on public comment periods and final rule publication. Cannabis stocks have already priced in much of the rescheduling optimism, with the AdvisorShares Pure US Cannabis ETF (MSOS) gaining over 60% since October 2023 when rescheduling momentum accelerated. NORML's engagement adds another layer of legitimacy to proceedings that could reshape the $30 billion US cannabis market.